Clarifies Cano’s Disingenuous Post-Meeting Press Release by Disclosing That More Than 75% of the Votes Cast WITHHELD Support for the Directors Standing for Re-Election

Condemns the Current Board’s Unwillingness to Accept That a Critical Mass of Stockholders Have Made Clear They Want New Leadership After an Extended Period of Abysmal Governance and Massive Value Destruction

Will Continue Pursuing Change at Cano Until the Company Rids Itself of CEO Marlow Hernandez, Chairman Sol Trujillo and Other Conflicted Directors

Elliot Cooperstone, Lewis Gold and Barry Sternlicht (collectively with certain of their affiliates, the “Group” or “we”), who recently resigned as members of the Board of Directors (the “Board”) of Cano Health, Inc. (“Cano” or the “Company”) (NYSE: CANO) and collectively represent the largest single stockholder of the Company, today announced that its proxy solicitor’s analysis of preliminary results indicates more than 75% of the votes cast WITHHELD support for the director candidates standing for election at the 2023 Annual Meeting of Stockholders (the “Annual Meeting”): Compensation Committee Chair Dr. Alan Muney and Nominating and Corporate Governance Committee Chair Kim Rivera.

The Group commented:

“We thank our fellow stockholders for the outpouring of encouragement and support during this initial stage of our campaign to turn around Cano. The outcome of the Annual Meeting, whereat more than 75% of the votes cast WITHHELD support for the directors up for re-election, represents a clear and striking referendum on the failures of Cano’s leadership. Unfortunately, the only party in denial about the need for sweeping changes appears to be the current Board. It speaks volumes about the Board’s arrogance and intransigence that it issued a post-meeting press release touting the re-election of directors who retained their seats solely due to the Company’s reliance on an archaic plurality voting policy – one that allows directors to be re-elected with a single vote for their election. Regardless of the Board’s apparent disdain for stockholders’ feedback, we will continue to pursue change through all available means until Dr. Marlow Hernandez, Sol Trujillo and other misaligned directors are no longer affiliated with the Company.”

Investors: HKL & Co., LLC Peter Harkins, Jr. / Jordan Kovler Toll-Free: (800) 326-5997 CANO@hklco.com

Media: Longacre Square Partners Greg Marose / Charlotte Kiaie, (646) 277-8813 gmarose@longacresquare.com / ckiaie@longacresquare.com

Cano Health (NYSE:CANO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Cano Health.
Cano Health (NYSE:CANO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Cano Health.